

## **ELECTRONIC SUPPLEMENTARY INFORMATION**

### **Manuscript title:**

**Economic burden of idiopathic pulmonary fibrosis in Spain: a prospective, real-world data study (OASIS study)**

Journal: PharmacoEconomics

### **Authors:**

Maria J. Rodríguez-Nieto, MD\*<sup>1</sup>, Esteban Cano-Jiménez, MD <sup>2</sup>, Ana D. Romero Ortiz, MD <sup>3</sup>, Ana Villar, MD <sup>4</sup>, Marta Morros<sup>5</sup>, Alba Ramon<sup>6</sup>, Silvia Armengol, MD <sup>6</sup>.

\*Corresponding author. E-mail: [mjrodriguezn@fjd.es](mailto:mjrodriguezn@fjd.es)

## Supplementary information SI1. Unit cost.


Unit costs and data sources used for costs analysis are described in the incruusted excel file. References used to identify unitarian costs are:

- Gisbert, R y Brosa, M. Base de datos de costes sanitarios y ratios coste-efectividad españoles: eSalud [Internet]. Barcelona: Oblikue Consulting, S.L; 2007 [última actualización: 2019 fecha consulta: enero 2020]. Disponible en: <http://www.oblikue.com/bddcostes/>
- Consejo General de Colegios Oficiales de Farmacéuticos (2017) Base de Datos de Medicamentos: Bot PLUS 2.0. [fecha consulta: enero 2020]. Disponible: <https://botplusweb.portalfarma.com/>.
- FACUA. Estudio comparativo de las tarifas de los taxis de 52 ciudades españolas (Octubre, 2018) [fecha consulta: 06/2019] Disponible en: [https://www.facua.org/es/documentos/estudio\\_tarifas\\_taxi\\_2018.pdf](https://www.facua.org/es/documentos/estudio_tarifas_taxi_2018.pdf)
- Ministerio de sanidad, consumo y bienestar social (2019). Orden SCB/45/2019, de 22 de enero. Boletín Oficial del Estado núm. 22, 25 de enero de 2019. Disponible en: <https://www.boe.es/boe/dias/2019/01/25/pdfs/BOE-A-2019-856.pdf>
- Ministerio de Sanidad Consumo y Bienestar Social. Instituto de Información Sanitaria. Registro de Altas 2017- CMBD [Internet]. 2020 [Accedido 30 enero 2020]. Disponible en: <http://pestadistico.inteligenciadegestion.msssi.es/publicoSNS/comun/DefaultPublico.aspx>



OASIS\_Table  
unitarian costs\_.xlsx

## Supplementary information SI2. Flow chart.



\*Evaluable patients for cost analysis included those patients with a follow-up of at least 6 months (T6).

<sup>1</sup>14 patients who died during between T6 and T12 were included in the evaluable patient (cost) and final living cost were imputed.

<sup>2</sup> discontinued at T6 and without specifying structural changes cost

**Supplementary information SI3. Summary table of p-values from the bivariate analysis for total annual-IPF-related costs (total sample).**

Variables	Response n	Non-response n	p
Age	180	0	0.0831
Time of IPF diagnosis	180	0	0.0392
FVC% predicted (T0)	180	0	0.0130
DLCO – predicted (T0)	169	11	0.0669
FVC% predicted (T6)	150	30	0.0465
FVC rate change by year (T12)	139	41	<0.0001
Pulmonary emphysema associated with IPF	180	0	0.0255
Antifibrotic treatment related to IPF along the study	180	0	<0.0001
Patients with acute exacerbations ( $\geq 1$ acute exacerbation)	180	0	0.0399
Patients according FVC % predicted in T0	180	0	0.0002

NOTE: Non-response= n – Response n

The variable FVC% predicted (T0), FVC% predicted (T6) and FVC rate change by year (T12) were not inserted in the multivariate model due to collinearity with Patients according FVC % predicted in T0.

**Supplementary information SI4. Linear regression analysis on the variation in cost according to the FVC decline (relative change through 12 months period) in total sample.**

Parameter	df	Estimate (95% Confidence Limits)	SE	T Value	Pr >  t
Intercept	1	28,809.109 (26,188.232; 31,429.986)	1,325.43925	21.74	<.0001
FVC decline (relative change)	1	409.37032 (284.01645; 534.72418)	63.39637	6.46	<.0001

Goodness of fit: R-square: 0.2320.

FVC decline (relative change)= (FVC (T12) – FVC (T0))/ FVC (T0) x 100%